CoChat

Primary central nervous system lymphoma

Open access
Ferreri, Andrés J. M., Calimeri, Teresa, Cwynarski, Kate, Dietrich, Jorg, Grommes, Christian, Hoang-Xuan, Khê, Hu, Leland S., Illerhaus, Gerald, Nayak, Lakshmi, Ponzoni, Maurilio, Batchelor, Tracy T. · 2023 · Nature Reviews Disease Primers
Cited by 252

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

This Primer summarizes the epidemiology, pathophysiology, diagnosis and treatment of primary central nervous system lymphoma. This Primer also reviews future research avenues and the effect that this disorder has on the quality of life of patients. Primary central nervous system lymphoma (PCNSL) is a diffuse large B cell lymphoma in which the brain, spinal cord, leptomeninges and/or eyes are exclusive sites of disease. Pathophysiology is incompletely understood, although a central role seems to comprise immunoglobulins binding to self-proteins expressed in the central nervous system (CNS) and alterations of genes involved in B cell receptor, Toll-like receptor and NF-κB signalling. Other factors such as T cells, macrophages or microglia, endothelial cells, chemokines, and interleukins, probably also have important roles. Clinical presentation varies depending on the involved regions of the CNS. Standard of care includes methotrexate-based polychemotherapy followed by age-tailored thiotepa-based conditioned autologous stem cell transplantation and, in patients unsuitable for such treatment, consolidation with whole-brain radiotherapy or single-drug maintenance. Personalized treatment, primary radiotherapy and only supportive care should be considered in unfit, frail patients. Despite available treatments, 15–25% of patients do not respond to chemotherapy and 25–50% relapse after initial response. Relapse rates are higher in older patients, although the prognosis of patients experiencing relapse is poor independent of age. Further research is needed to identify diagnostic biomarkers, treatments with higher efficacy and less neurotoxicity, strategies to improve the penetration of drugs into the CNS, and roles of other therapies such as immunotherapies and adoptive cell therapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41572-023-00439-0

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Metadata

Authors
Ferreri, A. J. M., Calimeri, T., Cwynarski, K., Dietrich, J., Grommes, C., Hoang-Xuan, K., Hu, L. S., Illerhaus, G., Nayak, L., Ponzoni, M., & Batchelor, T. T.
Venue
Nature Reviews Disease Primers
Published
2023-06-15
Volume
9
Issue
1
Pages
29-29
ISSN
2056-676X (ISSN-L)
OpenAlex
W4380790188
Cited by
252
References
5
FWCI
11.97
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Primary central nervous system lymphoma. https://app.cochat.ai/papers/10.1038/s41572-023-00439-0
The paper
Ferreri, A. J. M., Calimeri, T., Cwynarski, K., Dietrich, J., Grommes, C., Hoang-Xuan, K., Hu, L. S., Illerhaus, G., Nayak, L., Ponzoni, M., & Batchelor, T. T. (2023). Primary central nervous system lymphoma. Nature Reviews Disease Primers. https://doi.org/10.1038/s41572-023-00439-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.